A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) har...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Res Treat
Main Authors: Park, Cheol-Kyu, Cho, Hyun-Ju, Choi, Yoo-Duk, Oh, In-Jae, Kim, Young-Chul
Format: Artigo
Language:Inglês
Published: Korean Cancer Association 2019
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6473264/
https://ncbi.nlm.nih.gov/pubmed/30189719
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.387
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items